U.S. Oil and Gas Stock News

NasdaqGS:FLEX
NasdaqGS:FLEXElectronic

US Stock Market Today S&P 500 Futures Edge Higher As Rate Relief Hopes Build

The Morning Bull - US Market Morning Update Thursday, May, 7 2026 E-mini S&P 500 futures are a touch higher this morning, as investors weigh easing tensions in the Middle East against fresh signs of a mixed global economy. Hopes for progress in US Iran talks have pushed oil prices lower and pulled the US 10 year Treasury yield down to around 4.35%, which can ease borrowing costs for households and companies. At the same time, US private employers added 109,000 jobs in April, the strongest...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors

Protagonist Therapeutics (PTGX) opened 2026 with Q1 revenue of US$56.4 million, Basic EPS of US$0.06 and net income of US$3.8 million, while trailing 12 month figures show revenue of US$74.1 million, a Basic EPS loss of US$1.79 and a net loss of US$114.7 million. Over the past year, the company has seen quarterly revenue move between US$4.7 million and US$170.6 million, alongside Basic EPS that has ranged from a US$2.11 profit to a US$0.69 loss. These figures give investors a broad set of...
NasdaqGS:POWL
NasdaqGS:POWLElectrical

Is It Too Late To Consider Powell Industries (POWL) After Its Surging Share Price?

If you are wondering whether Powell Industries at around US$320 per share still offers value, it helps to separate headline returns from what the underlying valuation is actually saying. The stock has posted very strong returns, with gains of 26.4% over the last week, 71.5% over the past month, 172.6% year to date and 451.6% over the last year, plus a multi year return of more than 17x. Recent coverage has focused on Powell Industries as part of broader discussions around power...
NasdaqGS:VECO
NasdaqGS:VECOSemiconductor

Veeco Instruments (VECO) Margin Compression And Q1 Loss Test Bullish Growth Narratives

Veeco Instruments (VECO) opened 2026 with Q1 revenue of US$158.3 million, basic EPS of roughly a US$0.01 loss, and trailing 12‑month EPS of US$0.39 on US$655.3 million of revenue, setting up a quarter where profitability was in focus. The company has seen quarterly revenue move from US$167.3 million and basic EPS of US$0.21 in Q1 2025 to US$158.3 million and a small loss in Q1 2026, while trailing 12‑month EPS moved from US$1.31 on US$717.3 million of revenue at Q4 2024 to US$0.39 on US$655.3...
NYSE:AIR
NYSE:AIRAerospace & Defense

Has AAR (AIR) Risen Too Far After Recent Aerospace And Defense Sector Interest

If you are wondering whether AAR at US$118.71 is still reasonably priced after a strong run, this article walks through what the current share price might imply about value. The stock has recent returns of 12.3% over 7 days, 4.1% over 30 days, 40.6% year to date and 101.0% over the last year, which naturally raises questions about how much upside or risk is now priced in. Recent headlines have focused on AAR's role within the broader Aerospace & Defense sector and how investors are reacting...
NasdaqGM:ADMA
NasdaqGM:ADMABiotechs

ASCENIV Pediatric Approval Tests ADMA Biologics Growth Story And Risks

FDA approves an expanded label for ASCENIV to include pediatric immunodeficiency patients aged two and older. The decision allows earlier intervention for immune compromised children and broadens ASCENIV’s eligible patient pool. The approval fulfills a key post marketing commitment for ADMA Biologics and may influence future commercial uptake. For ADMA Biologics (NasdaqGM:ADMA), this regulatory milestone arrives with the stock trading at $10.08 after a very large 5 year return and a 182.4%...
NYSE:ONTO
NYSE:ONTOSemiconductor

Onto Innovation (ONTO) Margin Reset From 21.3% To 10.3% Tests Bullish Growth Narratives

Onto Innovation (ONTO) has opened 2026 with Q1 revenue of US$291.9 million and basic EPS of US$0.68, setting a clear benchmark for how the rest of the year may shape up. The company has seen quarterly revenue move between US$218.2 million and US$291.9 million over the last six reported periods, while basic EPS has ranged from US$0.21 to US$1.30. This gives investors a concrete sense of how top line and per share earnings have tracked through recent cycles. With trailing 12 month net profit...
NYSE:PRGO
NYSE:PRGOPharmaceuticals

Perrigo (PRGO) Q1 Loss Of US$389.9 Million Tests Profit-Recovery Narratives

Perrigo (PRGO) opened Q1 2026 with revenue of US$969.2 million and a basic EPS loss of US$2.81, while net income excluding extra items came in at a loss of US$389.9 million. Over the past six reported quarters, revenue has ranged between US$969.2 million and US$1.14 billion and basic EPS has moved from a small profit of US$0.09 in Q3 2025 to a loss of US$10.20 in Q4 2025 and US$2.81 in the latest quarter, giving investors a wide view of how the income statement has changed across different...